ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 3ZYNLONTANeutral

AI Analysis

Summary

ADC Therapeutics announced topline results from the LOTIS-5 Phase 3 confirmatory trial evaluating ZYNLONTA in combination with rituximab for relapsed or refractory diffuse large B-cell lymphoma. The company hosted a conference call to discuss trial outcomes.

Clinical Trial Data

Phase

Phase 3

Importance:8/10

Sentiment:

0.00

Phase 3Data ReadoutOncologyZYNLONTALOTIS-5Rituximab Combination

Related Companies

$ADCT

Read the original article

Published by PR Newswire Clinical Trials on June 3, 2026 8:05 PM

Read Original